2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

9:00AM-11:00AM: Abstract Number: 1206

Performance of the Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29) Item Profile in a Cohort of Australians with RA, OA and Other Inflammatory Arthritic Conditions

Measures Of Healthcare Quality Poster II: Improving Care

9:00AM-11:00AM: Abstract Number: 1175

Periarticular Inflammation and Bone Marrow Oedema Are Important in the Evaluation of Enthesitis on MRI in Patients with Peripheral and Axial SpA

Imaging Of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 1396

Persistence of Tocilizumab Therapy Among Patients with Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry

RA – Treatments Poster II: Established Treatments

9:00AM-11:00AM: Abstract Number: 1505

Persistence with Etanercept in Patients with Ankylosing Spondylitis or Psoriatic Arthritis in Germany: A Real-World Analysis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1602

Persistency in Platelet C4d and Thrombosis Risk Score Associate with Thrombosis in Systemic Lupus Erythematosus

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1572

Persistent Cognitive Impairment in Lupus Patients over 1 Year and Associated Factors

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 1728

Persistent Disease Activity Is Associated with Avascular Necrosis Development in Juvenile Systemic Lupus Erythematosus

Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma

9:00AM-11:00AM: Abstract Number: 993

pH-Sensitive Nanoformulated Triptolide as a Targeted Therapeutic Strategy for Rheumatoid Arthritis

RA – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 1694

Pharmacogenetics and Pharmacodynamics of Response to Apremilast in a Phase 3 Clinical Study in Subjects with Active Behçet’s Disease

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides

9:00AM-11:00AM: Abstract Number: 1217

Phase 2 Dose-ranging Study of SEL-212 in Symptomatic Gout Patients: Selection of Doses for Further Clinical Development

Metabolic & Crystal Arthropathies Poster II: Clinical Trials & Basic Science

9:00AM-11:00AM: Abstract Number: 1128

Physician-Patient Interaction and Medication Adherence in Lupus Nephritis

Health Services Research Poster II – ACR/ARP

9:00AM-11:00AM: Abstract Number: 1061

PI3K-Akt Pathway Plays a Crucial Role in Production of Collagen in Fli1 Deficient Condition and Its Inhibitor Has the Therapeutic Potential in Treating Fibrosis

Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1216

Pilot, Randomized, Double-Blinded, Placebo Controlled Efficacy AndSafety Study of a Transdermal Alkalinizing and Pain Relieving Treatment ForAcute Gout Flare

Metabolic & Crystal Arthropathies Poster II: Clinical Trials & Basic Science

9:00AM-11:00AM: Abstract Number: 1617

Platelet Bound Complement Split Product (PC4d) May Be a Marker of Platelet Activation and Cardiovascular Events in Systemic Lupus Erythematosus

SLE – Clinical Poster II: Comorbidities

9:00AM-11:00AM: Abstract Number: 979

Platelet Derived Growth Factor Receptor Alpha (PDGFRα) Blockade Inhibits Arthritis in Mice

RA – Animal Models Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].